Big Moving Stock keep track of the biggest moving stocks in the market.


Nasdaq: GOOG NFLX AMZN TSLA WYNN ILMN AMGN COST SSYS GILD WDC AAPL TRIP SNDK CELG MNST DTV FANG ADP
Nyse: LNKD V IVV IBM GS LMT SPG FDX MMM CVX BA GD TMO WLP MON PH APC EOG SLB CAT
New Highs: REGN TSLA IBB IVV GS COO ORLY AAP AMGN NOC AMP FFIV URI UTHR GILD UNP SRE AAPL LEA EXP

The Hot Industries

Biotechnology 3
Auto Parts Stores 2
Gas Utilities 1

The Hot Sectors

Healthcare 5
Services 4
Consumer Goods 3

SPPI Stock Chart


SPPI
Analyze

Sector:

Healthcare
Daily

Industry:

Biotechnology
Weekly

Employees:

N/A
Monthly

Website:

http://www.sppirx.com

SPPI Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals, Inc., a biotechnology company, develops and commercializes oncology and hematology drug products. The company’s commercialized drug products include FUSILEV for the treatment of patients with metastatic colorectal cancer, rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma; ZEVALIN injection for intravenous use as a prescription medication; and MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation of the anticancer drug vincristine for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. It also develops BELEODAQ for the treatment of various hematological and solid tumors; Captisol-enabled MELPHALAN, an intravenous formulation of MELPHALAN for clinicians and patients in the multiple myeloma transplant setting; APAZIQUONE to treat non-muscle invasive bladder cancer; and SPI-2012 for the treatment of chemotherapy-induced neutropenia. The company sells its drugs through a direct sales force in the United States; and through distributors in Europe and Japan. It has licensing and development agreement with Cell Therapeutics, Inc.; license agreement with Merck & Cie AG and Cydex Pharmaceuticals, Inc.; development and commercialization collaboration agreement with Allergan; collaboration agreement with Nippon Kayaku Co., Ltd.; licensing and collaboration agreement with TopoTarget A/S; and co-development and commercialization agreement with Hanmi Pharmaceutical Company. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.

favicon

Why Spectrum Fell on Beleodaq Approval but Will Rocket on Melphalan Approval

18 Aug 2014, 12:18 pmSpectrum's Beleodaq for Non-Hodgkin's lymphoma received FDA approval on July 3, but the stock then fell 26%. The same thing won't happen with Melphalan because sales numbers are already established. Click to view a price quote on SPPI . Click to research the Drugs industry.
favicon

Spectrum Pharmaceuticals (SPPI) Posts Strong Earnings in Q2 - Analyst Blog

12 Aug 2014, 11:10 amSpectrum Pharmaceuticals (SPPI) Posts Strong Earnings in Q2 - Analyst Blog
favicon

Spectrum Pharmaceuticals (SPPI) Posts Strong Earnings in Q2

12 Aug 2014, 8:30 amSpectrum Pharmaceuticals (SPPI) reported second-quarter 2014 earnings of 16 cents per share, compared to the year-ago loss of 15 cents.
favicon

Rodman & Renshaw 2014 Annual Global Investment Conference to be held in New York from September 8 to 10, 2014

11 Aug 2014, 6:00 amRodman & Renshaw Conferences, LLC, today announced that – former United States Secretary of State and retired four star general – Colin L. Powell will present the keynote address for the 2014 Rodman & Renshaw Annual Global Investment Conference, sponsored by H.C.
favicon

Spectrum Pharmaceuticals Reports 45% Sales Growth in the Second Quarter, Launches Fifth Product and Moves Closer to a ...

7 Aug 2014, 2:00 pmSpectrum Pharmaceuticals, Inc. , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and onc
favicon

Deep Dive: These eight health-care stocks could rise up to 75%

5 Aug 2014, 12:13 pmHealth-care stocks have outperformed the market so far this year. Here are eight stocks that could rise up to 75%, writes Philip Van Doorn.